AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,988.00p
   
  • Change Today:
    -38.00p
  • 52 Week High: 12,144.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.22m
  • Volume: 1,636,659
  • Market Cap: £185,840m
  • RiskGrade: 123

AstraZeneca to buy US-listed Fusion Pharma for $2bn

By Frank Prenesti

Date: Tuesday 19 Mar 2024

LONDON (ShareCast) - (Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,988.00p
Change Today -38.00p
% Change -0.32 %
52 Week High 12,144.00
52 Week Low 9,501.00
Volume 1,636,659
Shares Issued 1,550.22m
Market Cap £185,840m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
91.68% below the market average91.68% below the market average91.68% below the market average91.68% below the market average91.68% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
57.75% above the market average57.75% above the market average57.75% above the market average57.75% above the market average57.75% above the market average
82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average
Income
87.48% below the market average87.48% below the market average87.48% below the market average87.48% below the market average87.48% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average
Growth
81.84% above the market average81.84% above the market average81.84% above the market average81.84% above the market average81.84% above the market average
94.44% above the sector average94.44% above the sector average94.44% above the sector average94.44% above the sector average94.44% above the sector average

What The Brokers Say

Strong Buy 8
Buy 13
Neutral 6
Sell 0
Strong Sell 1
Total 28
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 26-Apr-2024

Time Volume / Share Price
16:36 400 @ 11,988.00p
16:36 600 @ 11,988.00p
16:36 53,995 @ 11,976.12p
16:35 680,675 @ 11,988.00p
16:35 2,636 @ 11,988.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page